Long-term effects of bisphosphonates on the growing skeleton studies of young patients with severe osteoporosis

Medicine

Volumn 76, Issue 4, 1997, Pages 266-283

  Brumsen, Caro ^a   Hamdy, Neveen A T ^a   Papapoulos, Socrates E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ADOLESCENT; ARTICLE; BONE GROWTH; CHILD; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; HUMAN; MALE; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL;

ADOLESCENT; BONE DENSITY; BONE DEVELOPMENT; CALCIUM; CHILD; DIPHOSPHONATES; FEMALE; HUMANS; MALE; OSTEOPOROSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; VITAMIN D;

EID: 0030788428     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005792-199707000-00005     Document Type: Article

References (109)

1. Adami S, Passen M, Ortolani S, Broggini M, Carratclli L, Caruso I, Gandolini G, Gncssi L, Laurenzi M, Lombardi A, Norbiato G, Pryor-Tillotson S, Reda C, Romanini L, Subrizi D, Wci L, Yates AJ. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 17:383-90, 1995.
2. Adami S, Zamberlan N. Adverse effects of bisphosphonates. A comparative review. Drug Safety 14:158-70, 1996.
3. Albright F, Reifenstein EC Jr. Osteoporosis of Cushing's syndrome. In: Parathyroid glands and metabolic bone disease. Baltimore: Williams & Wilkins, pp 165-88, 1918.
4. Albright JA. Systemic treatment of osteogenesis imperfecta. Clin Orthop Rel Res 159:88-96, 1981.
5. Avioli LV. Osteoporosis in rheumatoid arthritis. Arthritis Rheum 30: 830-31, 19S7.
6. Baron R, Gertner JM, Lang R, Vignery A, Increased bone turnover with decreased bone formation by osteoblasts in children with osteogenesis imperfecta tarda. Pediatr Res 17:204-7, 1983.
7. Bartal E, Gage JR. Idiopathic juvenile osteoporosis and scoliosis. J Pediatr Orthop 2:295-98, 1982.
8. Berglund G, Lindquist B. Osteopenia in adolescence. Clin Orthop 17: 259-64, 1960.
9. Bertelloni S, Baroncelli GI, Di Nero G, Saggese G. Idiopathic juvenile osteoporosis: Evidence of normal osteoblast function by 1, 25-dihydroxyvitamin D3 stimulation test Calcif Tissue Int 51:20-23, 1992.
10. Bianchi ML, Bardare II, Caraceni HP, Cohen E, Falvella S, Borzani II, DeGaspari MG. Bone metabolism in juvenile rheumatoid arthritis. Bone Miner 9:153-62, 1990.
11. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant UK, Haskeil WL, Marcus R, Ott SM, Tomer JC, Quandt SA, Reiss TF, Ensrud KE, for the Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:153541, 1996.
12. Bonjour J-P, Theintz G, Buchs B, Slosman D, Rizzoli R. Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J Clin Endocr Metab 73:555-63, 1991.
13. Boudailliez BR, Paulard BJ, Sebert J-L, Kremp O, Piussan CX. Leukaemia-associated hypercalcemia in a 10-year-old boy: Effectiveness of aminohydroxypropylidene biphosphonate. Pediatr Nephrol 4: 510-11, 1990.
14. Brenner RE, Vetter U, Bollen A-M, Mörike M, Eyre DR Bone résorption assessed by immunoassay of urinary cross-linked collagen peptides in patients with osteogenesis imperfecta. J Bone Miner Res 9: 993-97, 1994.
15. Brenton DP, Dent CE. Idiopathic juvenile osteoporosis. In: Bickel II, Stern J, eds. Inborn errors of calcium and bone metabolism. Lancaster. MTP Press, pp 222-38, 1976.
16. Cassidy JT, Langman CB, Alien SH, Ilillman IS. Bone mineral metabolism in children with juvenile rheumatoid arthritis. Pediatr Clin North Am 42:1017-33, 1995.
17. Castells S. Metabolic bone disease, to: lifshitz F, éd. Pédiatrie endocrinology. New York: Marcel Dekker, p 521-34, 1996.
18. Catel W. Pubertatsfischwirbelkrankheit Kinderärztl Praxis 22: 21-26, 1954.
19. Chesnut CH, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, Singer FR, Stock JL, Yood RA, Delmas PD, Kher U, Pryor-Tillotson S, Santora AC. Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling. Am J Med 99:144-62, 1995.
20. Cloutier MD, Hayles AB, Riggs BL, Jowsey J, Bickel WH. Juvenile osteoporosis: Report of a case including a description of some metabolic and microradiographic studies. Pediatrics 40:649-55, 1967.
21. Cumming WA. Idiopathic juvenile osteoporosis. J Can Assoc Radio! 21: 21-26, 1970.
22. Davie MWJ, Haddaway MJ. Bone mineral content and density in healthy subjects and in osteogenesis imperfecta. Arch Dis Child 70: 331-51, 1991.
23. Dent CE, Friedman M. Idiopathic juvenile osteoporosis. Q J Med 3-1: 177-210, 1965.
24. De Schepper J, Derde MP, van den Brocck M, Picpsz A, Jonckheer MIL Normative data for lumbar spine bone mineral content in children: Influence of age, height, weight and pubertal stage. J Nucl Med 32: 210-20, 1991.
25. Devogelaer JP, Malghem J, Maldague B, Nagant de Deuxchaisnes C. Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogencsis imperfecta. Skeletal Radiol 16: 360-63, 1987.
26. Dimar JR, Campbell M, Classman SD, Puno RM, Johnson JR. Idiopathic juvenile osteoporosis, an unusual cause of back pain in an adolescent Am J Orthop 2-4: S65-C9, 1993.
27. Elsasser U, Wilkins B, Hesp R, Thurnham DI, Reeve J, Ansell BM. Bone rarefaction and crush fractures in juvenile chronic arthritis. Arch Dis Child 57:377-SO, 1982.
28. Evans RA, Dunstan CR, Hills E. Bone metabolism in idiopathic juvenile osteoporosis: A case report. Calcif Tissue Int35:5-S, 1983.
29. Exner GU, Prader A, Elsasser U, Anliker M. Idiopathic osteoporosis in a three-year-old girl. Helv Paediatr Acta 39:517-28, 1984.
30. Fanconi A, Illig R, Poley JR, Prader A, Francillon M, Labhart A, Uehlinger E. Idiopathische transitorische Osteoporose im Pubertätsalter. Helv Paediatr Acta 21:531-47, 1966.
31. Fleisch II. The use of bisphosphonates in osteoporosis. Br J Clin Pract 48:323-26, 1994.
32. Glastrc C, Braillon P, David L, Cochat P, Meunier PJ, Delmas PD. Measurement of bone mineral content of the lumbar spine by dual energy X-ray absorptiometry in normal children: Correlations with growth parameters. J Clin Endocrinol Metab 70:1330-33, 1990.
33. Glorieux FH, Travers R, Lanoue G. Pamidronate treatment in children with fibrous dysplasia and osteogenesis imperfecta [abstract]. Bone 17:611, 1995.
34. Glorieux FI I, Norman ME, Travers R, Taylor A. Idiopathic juvenile osteoporosis. In: Christiansen C, Riis BJ, eds. Osteoporosis 1993. Copenhagen: Osteopress ApS, pp 200-2, 1993.
35. Gooding CA, Ball JH. Idiopathic juvenile osteoporosis. Radiology 93: 1319-50, 1969.
36. Görgenyi A. Idiopathic juvenile osteoporosis: Report of a case and review of the literature. Acta Paediatr Acad Sci Hung 10:315-21, 1969.
37. Grubbauer HM, Stögmann W, Wendler H. Differentialdiagnose und Verlauf der idiopathischen juvenilen Osteoporose. Hin Pädiat 188: 353-59, 1976.
38. Hammel H. Über die Osteoporose der Wirbelsäule unklarer Ursache (Fischwirbelkrankheit). Arch Orthop Unfallchir 44:412-15, 1951.
39. Hannan WJ, Cowen SJ, Wrate RM, Barton J. Improved prediction of bone mineral content and density. Arch Dis Child 72:147-49, 1995.
40. Harinck HIT, Papapoulos SE, Blanksma III, Moolenaar AJ, Vermeij P, Byvoet OLM. Paget's disease of bone: Early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). Br Med J 295: 1301-5, 1987.
41. Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P, Miller PD, Ldeata AA, Chesnut CH III. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy. Am J Med 95:557-67, 1993.
42. Hillman L, Cassidy JT, Johnson L, Lee D, Allen S! L Vitamin D metabolism and bone mineralization in children with juvenile rheumatoid arthritis. J Pediatr 124:910-16, 1994.
43. Hoekman K, Papapoulos SE, Peters ACB, Bjjvoet OLM. Characteristics of bisphosphonate treatment of a patient with juvenile osteoporosis. J Clin Endocrinol Metab 61:952-66, 1985.
44. Hopp R, Degan J, Gallagher JC, Cassidy JT. Estimation of bone mineral density in children with juvenile rheumatoid arthritis. J Rheumatol 18: 1235-39, 1991.
45. Houang MTW, Brenton DP, Renton P, Shaw DG. Idiopathic juvenile osteoporosis. Skeletal Radiol 3:17-23, 1978.
46. Huaux JP, Lokietek W. Case report Is APD a promising drug in the treatment of severe osteogenesis imperfecta? J Pediatr Orthop 8: 71-72, 1988.
47. Ishikawa S, Kumar SJ, Takahashi HE, Homma M. Vertebral body shape as a predictor of spinal deformity in osteogenesis imperfecta. J Bone Joint Surg (Am) 78:212-19, 1996.
48. Jackson EC, Strife CF, Tsang RC, Marder HK. Effect of calcitonin replacement therapy in idiopathic juvenile osteoporosis. Am J Dis Child 142:1237-39, 1988.
49. Jowsey J, Johnson KA. Juvenile osteoporosis: Bone findings in seven patients. J PediatrSl: 511-17, 1972.
50. Katzman DK, Bachrach LK, Carter DR, Marcus R. Clinical and anthropométrie correlates of bone mineral acquisition in healthy adolescent girls. J Clin Endocrinol Metab 73:1332-39, 1991.
51. Kooh SW, Cumming WA, Fraser D, Fomasier VL Transient childhood osteoporosis of unknown cause. In: Frame B, Parfitt AM, Duncan II, cds. Clinical aspects of bone disease. Princeton: Excerpta Medica, pp 329-32, 1973.
52. Kroger II, Kotaniemi A, Kroger L, Alhava E. Development of bone mass and bone density of the spine and femoral neck-a prospective study of 65 children and adolescents. Bone Miner 23:171-82, 1993.
53. Lachmann D, Willvonseder R, Höfer R, Bugajer-Gleitmann HE. A casereport of idiopathic juvenile osteoporosis with particular reference to 47-calcium absorption. Eur J Pediatr 125:265-73, 1977.
54. Landman JO, Schweitzer DH, Frölich M, Hamdy NAT, Papapoulos SE. Recovery of serum calcium concentrations following acute hypocalcemia in patients with osteoporosis on long-term oral therapy with the bisphosphonate pamidronate. J Clin Endocrinol Metab 80: 524-28, 1995.
55. Landman JO, Hamdy NAT, Pauwels EKJ, Papapoulos SE. Skeletal metabolism in patients with osteoporosis after discontinuation of longterm treatment with oral pamidronate. J Clin Endocrinol Metab SO: 34G5-G8, 1995.
56. Lapatsanis P, Kavadias A, Vretos K Juvenile osteoporosis. Arch Dis Child 46:66-71, 1971.
57. Lepore L, Pennesi M, Barbi E, Pozzi R. Treatment and prevention of osteoporosis in juvenile chronic arthritis with disodium clodronate. Clin Exp Rheumatol 9(Suppl 6): 33-35, 1991.
58. 2D) dans un cas d'ostéo-porose juvénile idiopathique. Arch Fr Pediatr 38:165-70, 1981.
59. Levis S, Gruber HE, Cohn D, Howard G A, Roos DA. Juvenile osteoporosis treated with pamidronate [abstract]. Calcif Tissue Int 52(Suppl 2): S41, 1993.
60. Liberman UA, Weiss SR, Broil J, Minne HW, Quan H, Bell Nil, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC H, Lombard! A, Shah RV, Hirsch IJ, Karpf DB. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The alendronate phase III osteoporosis treatment study group. N Engl J Med 333:1437-43, 1995.
61. Lindemann K. Über die Osteoporose der Wirbelsäule unklarer Ursache (Fischwirbelkrankheit). Arch Orthop Unfallchir 44:403-11, 1951.
62. Loirat C, Houllemare L, Lestradct II, Grenet P. L'osteoporose idiopathique de I'enfant-a propos d'un cas. Sem Hop Paris 43:2812-20, 1967.
63. Lu PW, Briody JN, Ogle GD, Morley K, Humphries IRJ, Allen J, Howman-GUes R, Sillence D, Cowell CR. Bone mineral density of total body, spine, and femoral neck in children and young adults: A crosssectional and longitudinal study. J Bone Miner Res 9:1451-58, 1994.
64. Marder UK, Tsang RC, Hug G, Crawford AC. Calcitriol deficiency in idiopathic juvenile osteoporosis. Am J Dis Child 136:914-17, 1982.
65. Marhaug G. Idiopathic juvenile osteoporosis. Scand J Rheumatol 22: 45-47, 1993.
66. Mclntyre HD, Cameron DP, Urquhart SM, Davies WE. Immobilization hypercalcaemia responding to intravenous pamidronate sodium therapy. Postgrad Med J 65:244-46, 1989.
67. Minisola S, Rosso R, Romagnoli E. Bone résorption assessed by immunoassay of urinary cross-linked collagen peptides in patients with osteogenesis imperfecta [letter]. J Bone Miner Res 10:335-36, 1995.
68. Papapoulos SE, Landman JO, Bvjvoet OLM, Löwik CWGM, Valkema R, Pauwels EKI, Vermeü P. The use of bisphosphonates in the treatment of osteoporosis. Bone 13: S41-S49, 1992.
69. Papapoulos SE. The role of bisphosphonates in the prevention and treatment of osteoporosis. Am J Med 95(Suppl 5A): 48S-52S, 1993.
70. Papapoulos SE. Bisphosphonates: Pharmacology and use in the treatment of osteoporosis. In: Marcus R, Feldman D, Kelsey J, eds. Osteoporosis. San Diego: Academic Press, pp 1209-34, 1996.
71. Paterson CR, McAUion S, SteUman JL. Osteogenesis imperfecta after the menopause. N Engl J Med 310:1694-96, 1984.
72. Persyn van Meerten EL, Kroon HM, Papapoulos SE. Epi- and metaphyseal changes in children caused by administration of bisphosphonates. Radiology 184:249-54, 1992.
73. Polito C, Strano CG, Rea L, Alessio M, lammarrone CS, Todisco N, Marotta A, laccarino E, Pirozzi M. Reduced bone mineral content and normal serum osteocalcin in non-steroid-treated patients with juvenile rheumatoid arthritis. Ann Rheum Dis 54:193-96, 1995.
74. Prockop DJ, Udenfriend S. A specific method for the analysis of hydroxyproline in tissues and urine. Anal Biochem 1:228-39, 1960.
75. Profumo RJ, Reese JC, Foy TM, Garibaldi LR, Kane RE. Severe immobilization-induced hypercalcemia in a child after liver transplantation successfully treated with pamidronate. Transplantation 57: 301-3, 1994.
76. Reed A, Haugen M, Pachman LM, Longman CD. Abnormalities in serum osteocalcin values in children with chronic rheumatic diseases. J Pediatr 116:574-80, 1990.
77. Reid IR, Wattie DJ, Evans MC, Gamble GD, Stapleton JP, Cornish J. Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab 79:1595-99, 1994.
78. Roede MJ, van Wieringen JC. Growth diagrams 19SO. Netherlands third nation-wide survey. Tydschr Soc Gez Zorg 63(Suppl 1): 1-34, 1985.
79. Rosskamp R, Sell G, Emons D, Issa S, Burmeister W. Idiopathische juvenile Osteoporose-Bericht über zwei Fälle. KUn Pädiat 199:457-61, 1987.
80. SO. Saggese G, Bertelloni S, Baroncelli G, Perri G, Calderazzi A. Mineral metabolism and calcitriol therapy in idiopathic juvenile osteoporosis. Am J Dis Child 145:457-4)2, 1991.
81. Samuel R, Katz K, Papapoulos SE, Yosipovitch Z, Zaizov R, Liberman UA. Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher's disease. Pediatrics 94:385-89, 1991.
82. Sauvegrain J, Leroy D, Finidori G, Kalifa G. Osteoporose juvénile idiopathique. J Radiol 60:821-24, 1979.
83. Schippers JC. Over een geval van "spontane" algemeene Osteoporose by een klein meisje. Maandschr Kindergeneeskunde 8:107, 1938.
84. Schuster W. Osteoporose im Kindesalter. Orthopäde 3:72-78, 1974.
85. Schwarz G. Orale Calciumtherapie bei zwei Fällen von juveniler idiopatischer Osteoporose. Verh Dtsch Ges Inn Med 71:884-89, 1965.
86. Schweitzer DU, Oostendorp-van de Ruit M, van der PImjm G, Löwik CWGM, Papapoulos SE. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogencontaining bisphosphonate dimethylaminohydroxypropylidene. J Bone Miner Res 10:956-62, 1995.
87. Seiler G. "Idiopathische" Osteoporose des Pubertätsalters. Fortschr Med 86:1031-33, 1968.
88. Shapiro JR. Comment [letter]. J Bone Miner Res 10:338-39, 1995.
89. Shaw NJ, White CP, Fraser VD, Rosenbloom L. Osteopenia in cerebral palsy. Arch Dis Child 71:235-38, 1991.
90. Shore RM, Langman CB, Donovan JM, Conway JJ, Poznanski AK. Bone mineral disorders in children: Evaluation with dual X-ray absorptiometry. Radiology 196:535-40, 1995.
91. Sillence D. Osteogenesis imperfecta: An expanding panorama of variants. Clin Orthop Rel Res 159:11-25, 1981.
92. Smith R. Idiopathic osteoporosis in the young. J Bone Joint Surg 62-B: 417-27, 1980.
93. Smith R. Idiopathic juvenile osteoporosis: Experience of twenty-one patients. Br J Rheumatol 34:68-77, 1995.
94. Southard RN, Morris JD, Mahan JD, Hayes JR, Torch MA, Sommer A, Zipf WB. Bone mass in healthy children: Measurement with quantitative DXA. Radiology 179:735-38, 1991.
95. Ste Marie LG, Charhon SA, Edouard C, Chapuy MC, Meunier PJ. Iliac bone histomorphometry in adults and children with osteogenesis imperfecta. J Clin Pathol 37:1081-89, 1984.
96. Storm T, Thamsborg G, Stemiche T, Genant HK, Sörensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Eng] J Med 322: 1265-71, 1990.
97. Tanner JM. Growth at adolescence. 2nd ed. Oxford: Blackwell, 1962.
98. Teotia M, Teotia SPS, Singh RK. Idiopathic juvenile osteoporosis. Am J Dis Child 133:894-900, 1979.
99. Theintz G, Buchs B, Rizzoli R, Slosman D, Clavien H, Sizonenko PC, Bonjour J-Ph. Longitudinal monitoring of bone mass accumulation in healthy adolescents: Evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects. J Clin Endocrinol Metab 75:1060-65, 1992.
100. Tick D, Singer F, Rimoin D. Pamidronate disodium in the treatment of idiopathic juvenile osteoporosis [abstract]. Am J Hum Genet 49: S180, 1991.
101. Valkema R, Vismans FJFE, Papapoulos SE, Pauwels EKJ, Büvoet OLM. Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner 5:183-92, 1989.
102. Varonos S, Ansell BM, Reeve J. Vertebral collapse in juvenile chronic arthritis: Its relationship with glucocorticoid therapy. Calcif Tissue Int 41:75-78, 19S7.
103. Vetter U, Pontz B, Zauner E, Brenner RE, Spranger J. Osteogenesis imperfccta: A clinical study of the first ten years of life. Calcif Tissue Int 50:36-J1, 1992.
104. Villanueva AR, Frost IIM. Bone formation in human osteogenesis imperfecta, measured by tetracycline bone labeling. Acta Orthop Scand 41: 531-38, 1970.
105. Vismans FJFE, Byvoet OLM, Peters ACB, Bots GThAM. Idiopatische juveniele osteoporose. Ned Ttjdschr Geneeskd 123:1508-13, 1979.
106. Wang Q, Marini JC. Antisense oligodeoxynucleotides selectively suppress expression of the mutant a2(T)collagen allele in type IV osteogenesis imperfecta fibroblasts. J Clin Invest 97:418-5-4, 1996.
107. Willing MC, Pruchno CJ, Byers PH. Molecular heterogeneity in osteogenesis type I. Am J Med Genet 45:223-27, 1993.
108. Woo PMM. Growth retardation and osteoporosis in juvenile chronic arthritis. Clin Exp Rheumatol 12(Suppl 10): S87-S90, 1994.
109. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical report series no. 843. Geneva: World Health Organization, 1994.